# A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

> **NCT04559971** · EARLY_PHASE1 · COMPLETED · sponsor: **Silence Therapeutics plc** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** SLN124
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04559971
- **Lead sponsor:** Silence Therapeutics plc
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-03
- **Primary completion:** 2021-03-23
- **Final completion:** 2021-03-23
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04559971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04559971, "A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04559971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*